New studies reveal predictors for avoidable RA hospitalizations, PsA transition in psoriasis & the impact of neighborhood on childhood lupus.
Atherosclerosis in Patients with SLE & the Risk of Progression: A 10-Year View
Research from Papazoglou et al. highlights the substantial risk of atherosclerosis progression and incident cardiovascular events in patients with systemic lupus erythematosus, as well as the importance of prolonged remission and the sustained control of cardiovascular risk factors in mitigating these risks over time.
Gout & Its Comorbidities
At ACR Convergence 2023, experts addressed important topics in gout research, including treating and preventing gout flares, lowering urate levels and managing comorbidities, as well as racial inequities in gout treatment, disease burden and outcomes.
Heart to Heart: Cardiovascular Disease in Autoimmune Conditions
During the ACR Convergence 2021 Review Course, Joan Bathon, MD, discussed cardiovascular manifestations of autoimmune diseases, including rheumatoid arthritis.
Study Finds NSAIDs Raise Heart Disease Risk in Osteoarthritis Patients
In a controlled, large-cohort, longitudinal study from Canada, Atiquazzaman et al. found that use of non-steroidal anti-inflammatory drugs (NSAIDs) substantially contributes to increased cardiovascular disease risk among people with osteoarthritis (OA).1 This is the first study to evaluate the mediating role that NSAIDs play in the association between OA and cardiovascular disease (CVD), and the…
Study Finds Renal Arteriosclerosis Is Common in Lupus Nephritis Patients
Renal arteriosclerosis is common in lupus patients with nephritis and occurs two decades earlier than it does in people without lupus nephritis (LN), report investigators in a study that examined the prevalence of renal arteriosclerosis in LN patients compared with healthy controls.1 The finding suggests that renal arteriosclerosis could be used as a biomarker for…
Study Examines Tofacitinib’s Long-Term Cardiovascular Risk & More
In a post-marketing safety study, tofacitinib did not prove non-inferior to tumor necrosis factor inhibitors when evaluated for its long-term effects on heart disease, malignancies and serious infections in RA patients.
Coronary Microvascular Dysfunction May Predict Heart Disease in Rheumatoid Arthritis
Cardiovascular disease (CVD) is a leading cause of death in patients with rheumatoid arthritis (RA). Patients with RA have a 1.5 times increased risk for heart attack compared with the general population. Although the treatment of RA has advanced significantly, the ability to prevent cardiovascular events hasn’t followed. A study in Arthritis Care & Research…
Biologics May Prevent Cardiovascular Events in RA Patients
RA patients experience a higher rate of cardiovascular disease (CVD) events than controls. In a new study, Karpouzas et al. determined that current biologic disease-modifying anti-rheumatic drug use is associated with reduced long-term CVD risk, protective calcification of noncalcified lesions and a lower likelihood of new plaque formation in patients with early atherosclerosis.
Cardiovascular Risk in Rheumatoid Arthritis: Pathogenesis, Screening & Prevention
SNOWMASS VILLAGE, COLO.—Even in the era of treat to target, cardiovascular disease risk remains elevated and is a major source of mortality and morbidity in patients with rheumatoid arthritis (RA). Screening and management of cardiovascular risk in these patients is critical to ensure these patients are identified and treated. At the 2019 ACR Winter Rheumatology…
- 1
- 2
- 3
- …
- 5
- Next Page »